Coherus BioSciences, Inc. Forecasted to Earn FY2028 Earnings of $0.08 Per Share (NASDAQ:CHRS)

Coherus BioSciences, Inc. (NASDAQ:CHRS) – Equities research analysts at HC Wainwright issued their FY2028 earnings per share estimates for Coherus BioSciences in a research note issued on Monday, September 16th. HC Wainwright analyst D. Tsao forecasts that the biotechnology company will post earnings of $0.08 per share for the year. HC Wainwright currently has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Coherus BioSciences’ current full-year earnings is ($1.07) per share.

Other equities analysts have also recently issued research reports about the stock. StockNews.com cut shares of Coherus BioSciences from a “buy” rating to a “hold” rating in a research report on Friday, September 6th. Robert W. Baird dropped their price target on Coherus BioSciences from $9.00 to $8.00 and set an “outperform” rating on the stock in a research report on Monday, July 1st. Finally, UBS Group downgraded shares of Coherus BioSciences from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $4.00 to $1.50 in a report on Friday, August 16th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Coherus BioSciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $6.92.

Coherus BioSciences Trading Down 9.7 %

Coherus BioSciences stock opened at $1.02 on Thursday. The stock has a 50 day moving average of $1.40 and a 200-day moving average of $1.80. The stock has a market cap of $117.02 million, a P/E ratio of -1.31 and a beta of 0.66. Coherus BioSciences has a 52 week low of $1.01 and a 52 week high of $4.48.

Coherus BioSciences (NASDAQ:CHRS) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.10. The firm had revenue of $64.98 million during the quarter, compared to analysts’ expectations of $57.08 million.

Institutional Investors Weigh In On Coherus BioSciences

A number of institutional investors and hedge funds have recently modified their holdings of CHRS. Nisa Investment Advisors LLC raised its position in Coherus BioSciences by 2,672.8% during the second quarter. Nisa Investment Advisors LLC now owns 20,657 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 19,912 shares during the period. TrinityPoint Wealth LLC acquired a new position in Coherus BioSciences during the fourth quarter valued at approximately $40,000. TIAA Trust National Association acquired a new stake in shares of Coherus BioSciences in the second quarter worth $47,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Coherus BioSciences by 66.4% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 21,426 shares of the biotechnology company’s stock worth $51,000 after buying an additional 8,546 shares during the period. Finally, Bayesian Capital Management LP bought a new position in Coherus BioSciences in the 1st quarter worth $56,000. 72.82% of the stock is owned by institutional investors and hedge funds.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.